BrainVectis' aim is to develop gene therapy treatments for neurodegenerative diseases by targeting the cholesterol pathway in the brain. Based on work carried out by Nathalie Cartier-Lacave and her team at the UMR1169 unit (INSERM/CEA) and by her collaborators (INSERM/UMR-S 1130, UMR 8246-CNRS), BrainVectis is hosted at MIRCen (CEA, Fontenay aux Roses).